NCAPG confers trastuzumab level of resistance by means of triggering SRC/STAT3 signaling pathway within HER2-positive breast cancer
https://www.selleckchem.com/products/fg-4592.html
Like
Comment
Share
NCAPG confers trastuzumab level of resistance by means of triggering SRC/STAT3 signaling pathway within HER2-positive breast cancer
https://www.selleckchem.com/products/fg-4592.html